Physician profile
Julia Caudill
NPI 1891223798
$1,343.12
in general payments reported to CMS, 2019-2025
26 companies · $384 in 2025
The $384 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $110 · 2023: $429 · 2024: $421 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,233.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $297.44 | 2022-2025 | |
| Myriad Genetic Laboratories, INC. | $264.00 | 2023 | Myrisk |
| Intera Oncology, INC | $93.80 | 2025 | Intera |
| Genentech USA, INC. | $71.43 | 2023-2025 | Tecentriq, Lunsumio, Columvi |
| Idorsia Pharmaceuticals US INC | $59.43 | 2022 | |
| Tempus Ai, INC | $57.28 | 2024-2025 | Xt Cdx |
| Astrazeneca Pharmaceuticals LP | $48.78 | 2024 | Imfinzi |
| Merck Sharp & Dohme LLC | $47.86 | 2024 | Keytruda, Lynparza |
| Caris Mpi, INC. | $40.13 | 2025 | Mi Cancer Seek |
| Aveo Pharmaceuticals, INC. | $32.54 | 2023 | Fotivda |
| Seagen INC. | $31.76 | 2023 | Tukysa, Adcetris |
| Iovance Biotherapeutics, INC. | $31.22 | 2025 | Amtagvi |
| Janssen Biotech, INC. | $27.54 | 2022-2025 | Tecvayli |
| Acera Surgical, INC. | $25.53 | 2025 | Restrata Wound Matrix |
| Novartis Pharmaceuticals Corporation | $21.33 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $20.88 | 2024 | Quikclot |
| Boston Scientific Corporation | $19.74 | 2024 | Spaceoar Vue System - 10ml |
| Regeneron Healthcare Solutions, INC. | $19.41 | 2023 | Libtayo |
| Polynovo North America LLC | $19.27 | 2024 | Novosorb Btm |
| Rigel Pharmaceuticals, INC. | $19.13 | 2023-2024 | Rezlidhia, Tavalisse |
| Bayer Healthcare Pharmaceuticals INC. | $17.61 | 2025 | |
| Kerecis Limited | $17.50 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Adaptive Biotechnologies Corporation | $15.47 | 2024 | Clonoseq |
| Lilly USA, LLC | $15.42 | 2023 | Retevmo, Verzenio |
| Exact Sciences Corporation | $15.16 | 2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $13.46 | 2025 | Ninlaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Caudill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.